Education
About Us
Working with TipRanks
Follow Us
Champions Oncology (CSBR)
:CSBR
CSBR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.60 - $11.99
Previous CloseN/A
Volume27.06K
Average Volume (3M)44.41K
Market Cap
$135.29M
Enterprise Value$59.12M
Total Cash (Recent Filing)$2.75M
Total Debt (Recent Filing)$6.78M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Jul 17, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding13,819,236
10 Day Avg. Volume47,274
30 Day Avg. Volume44,414
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.53
Price to Cash Flow (P/CF)-119.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.85
Enterprise Value/Ebitda41.23
Forecast
1Y Price Target
$12.00Price Target Upside25.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Champions Oncology News
PremiumCompany Announcements
Champions Oncology Reports Record Revenue and Strategic Growth
PremiumCompany Announcements
Champions Oncology Achieves Record Revenue and Profit
PremiumCompany Announcements
Champions Oncology Posts Strong Quarterly Revenue Growth
---
Ownership Overview
14.27% Insiders
3.02% Mutual Funds
34.50% Other Institutional Investors
45.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CSBR FAQ
What was Champions Oncology’s price range in the past 12 months?
Champions Oncology lowest stock price was $3.60 and its highest was $11.99 in the past 12 months.
What is Champions Oncology’s market cap?
Champions Oncology’s market cap is $135.29M.
When is Champions Oncology’s upcoming earnings report date?
Champions Oncology’s upcoming earnings report date is Jul 17, 2025 which is in 126 days.
How were Champions Oncology’s earnings last quarter?
Champions Oncology released its earnings results on Mar 11, 2025. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.37.
Is Champions Oncology overvalued?
According to Wall Street analysts Champions Oncology’s price is currently Undervalued.
Does Champions Oncology pay dividends?
Champions Oncology does not currently pay dividends.
What is Champions Oncology’s EPS estimate?
Champions Oncology’s EPS estimate is -0.2.
How many shares outstanding does Champions Oncology have?
Champions Oncology has 13,819,236 shares outstanding.
What happened to Champions Oncology’s price movement after its last earnings report?
Champions Oncology reported an EPS of $0.36 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Champions Oncology?
Currently, no hedge funds are holding shares in CSBR
---
Champions Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (25.65% Upside)
$12.00 (25.65% Upside)
Blogger Sentiment
Bullish
CSBR Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.43%
12-Months-Change
Fundamentals
Return on Equity
-154.52%
Trailing 12-Months
Asset Growth
-10.79%
Trailing 12-Months
Company Description
Champions Oncology
Champions Oncology, Inc. operates within the biotechnology sector, focusing on the development and sale of advanced technology solutions and services to enhance the drug development process, particularly in oncology. The company's core offerings include unique patient-derived xenograft (PDX) models that simulate human cancer tumors, providing valuable insights into cancer biology and facilitating the development of personalized medicine. Champions Oncology's services are crucial in aiding pharmaceutical and biotechnology companies in their research and development efforts to bring innovative cancer therapies to market.
---
CSBR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected significant positive developments such as record-breaking revenue, successful data licensing, and improved financial metrics. However, challenges in the biotech sector and uncertainties regarding future data revenue contributions were highlighted. Despite the challenges, the company is optimistic about long-term growth.Read More>---
CSBR Stock 12 Month Forecast
Average Price Target
$12.00
▲(25.65% Upside)
Technical Analysis
Best Analysts Covering CSBR
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+18.90%
reiterated a buy rating 3 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +18.90% per trade.
---